The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPOView Video
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plantView Video

Latest Share Chat

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,761.00
Bid: 1,757.50
Ask: 1,758.00
Change: 27.50 (1.59%)
Spread: 0.50 (0.028%)
Open: 1,736.00
High: 1,767.00
Low: 1,736.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London close: FTSE closes in positive territory, pharma stocks lead

Tue, 22nd Apr 2014 16:15

- FTSE closes up 56.51 points at 6,681.76- Easter weekend retail sales disappoint- Monthly US existing home sales down 0.4 per cent techMARK 2,738.48 +2.18%FTSE 100 6,681.76 +0.85%FTSE 250 16,082.24 +1.10%The FTSE 100 closed on an upbeat note today, having touched 6,700 earlier in the session as gains in the pharmaceutical sector drove sentiment higher on the back of a mix of major deals and M&A speculation. The top tier index closed up 56.51 points at 6,681.76, after having been shut since Thursday following the long Bank Holiday weekend. IG's Chief Market Strategist, Brenda Kelly, said: "The UK market has come back to the fray in fine form today, rising on the back of merger and acquisition activity as it strains to put the volatility of April behind it. However, those with a longer-term view will be carefully eyeing the top end of the current trading range. "Since mid-March we have bounced between 6500 and 6700 without establishing any real direction. The activity in the pharma sector is perhaps the first real sign of activity for a number of weeks, but even now 6700 is proving to be quite the hurdle."Indeed, it is certainly not all good news, with UK retail numbers for the long weekend coming in notably worse than even 2013's cold and wet Easter, with analysts blaming the still-fragile nature of consumer confidence. Retail footfall was below 2013 figures across all destinations, with average footfall on Good Friday down 7.6%, and 8.7% on Easter Saturday, according to data from retail data company Springboard."People are clearly still very nervous about spending and these figures reveal the fragility of the recovery," said Springboard's Marketing and Insights Director, Diane Wehrle.However, although High Street shops were competing with one of the coldest and wettest Easter weekends ever recorded in the country in 2013, numbers still fell 8.4% and 10.7% across the two days. Over in the States the news was a bit more positive, with existing home sales down 0.4% month-on-month in March, to an annualised pace of 4.59m, dropping from the 4.6m clip observed in the month before, according to the National Association of Realtors (NAR). The consensus estimate had been for a print of 4.55m.The lobby group pointed to rising prices and severe winter weather as the main causes behind the slip. Reflecting on the broadly positive corporate earnings reports coming out from the US, Kelly predicted that we are now "only another modestly positive session away from seeing 16,600 once again on the Dow Jones", which she believes is "an indication perhaps that this remains a market that wants to go up". Broker comment drives Shire into the top spotJefferies gave Shire a boost after it raised its target price for the pharmaceuticals group from 3,400p to 3,550p and kept a 'buy' rating, saying that the recent share-price weakness has presented an "attractive buying opportunity". The broker trimmed its estimates due to "sluggish" first-quarter ADHD prescriptions trends in the States, but still believes that group earnings will growth at a "robust" 13% rate over 2013-2018.GlaxoSmithKline (GSK) also jumped after announcing a massive three-part deal with Swiss pharmaceuticals peer Novartis, which will see shareholders receive a £4bn capital return. Killik maintained a 'buy' recommendation on GSK, saying that the deal will accelerate growth, provide cost savings and generate increased returns.AstraZeneca was rising strongly on speculation that Pfizer could make a takeover approach for the company, in a transaction valued in the region of £60bn, representing the biggest deal ever in the industry's history and the largest foreign takeover of a UK business on record. While AstraZeneca reportedly rejected the informal offer, Analyst Andrew Baum from Citigroup said he expected Pfizer to "push aggressively ahead with a second approach". US companies Eli Lilly and Allergan were also making headlines on the back of M&A speculation today.Meanwhile, Babcock fell despite an upgrade from 'hold' to 'buy' from Investec. Randgold, Fresnillo, Rio Tinto and Anglo American were all firmly in the red, hit by concerns about the Chinese economy, which suffered a slowdown in first quarter growth.On the second tier index, telecoms provider Colt fell sharply after it said margin pressures chipped away at quarterly earnings as it warned full-year earnings before interest, taxes, depreciation, and amortisation (EBITDA) before restructuring charges are expected to range between 5% and 10% below current consensus estimates.FTSE 100 - RisersShire Plc (SHP) 3,146.00p +7.56%GlaxoSmithKline (GSK) 1,640.00p +5.20%AstraZeneca (AZN) 3,960.00p +4.72%Sports Direct International (SPD) 830.00p +3.88%Hargreaves Lansdown (HL.) 1,247.00p +3.66%William Hill (WMH) 332.40p +3.20%Royal Mail (RMG) 522.00p +2.55%Persimmon (PSN) 1,325.00p +2.55%Weir Group (WEIR) 2,627.00p +2.50%Experian (EXPN) 1,107.00p +2.41%FTSE 100 - FallersRandgold Resources Ltd. (RRS) 4,605.00p -2.40%Fresnillo (FRES) 848.00p -2.30%Babcock International Group (BAB) 1,191.00p -2.06%Standard Chartered (STAN) 1,311.50p -1.06%Rio Tinto (RIO) 3,257.00p -0.96%Ashtead Group (AHT) 900.50p -0.77%Anglo American (AAL) 1,538.50p -0.55%HSBC Holdings (HSBA) 614.90p -0.40%Unilever (ULVR) 2,609.00p -0.31%Tullow Oil (TLW) 865.00p -0.29%FTSE 250 - RisersOcado Group (OCDO) 374.00p +6.80%Worldwide Healthcare Trust (WWH) 1,288.00p +6.01%Xaar (XAR) 900.00p +5.14%Hikma Pharmaceuticals (HIK) 1,570.00p +4.95%Moneysupermarket.com Group (MONY) 186.60p +4.89%JD Sports Fashion (JD.) 1,817.00p +4.73%Intermediate Capital Group (ICP) 450.80p +4.40%Evraz (EVR) 94.90p +4.17%BTG (BTG) 551.50p +4.15%Heritage Oil (HOIL) 266.90p +4.01%FTSE 250 - FallersCOLT Group SA (COLT) 130.00p -10.16%African Barrick Gold (ABG) 250.20p -3.44%QinetiQ Group (QQ.) 217.50p -1.85%Centamin (DI) (CEY) 52.90p -1.58%EnQuest (ENQ) 126.60p -1.56%PayPoint (PAY) 1,163.00p -1.44%Spirent Communications (SPT) 96.60p -1.43%Domino's Pizza Group (DOM) 516.00p -1.34%Merlin Entertainments (MERL) 352.20p -1.15%Britvic (BVIC) 739.00p -1.07%NR
More News
Today 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
2 May 2024 19:57

GSK knew about Zantac cancer risk, attorneys tell jury in first trial

May 2 (Reuters) - U.S. attorneys for a woman who claims her colon cancer was caused by the now discontinued heartburn drug Zantac on Thursday told a jury in Chicago that pharmaceutical companies GSK and Boehringer Ingelheim knew the product could cause cancer if it was not handled properly but failed to warn the public.

Read more
2 May 2024 09:48

LONDON BROKER RATINGS: Deutsche Bank likes TP ICAP but says sell CMC

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday:

Read more
1 May 2024 19:39

Bird flu testing shows more dairy products are safe, US FDA says

CHICAGO, May 1 (Reuters) - Preliminary results of tests on additional dairy products show that pasteurization inactivates the bird flu virus, the U.S. Food and Drug Administration said on Wednesday.

Read more
1 May 2024 17:31

UK's FTSE 100 slips ahead of Fed outcome, energy stocks weigh

FTSE 100 down 0.3%, FTSE 250 off 0.2%

*

Read more
1 May 2024 16:56

LONDON MARKET CLOSE: FTSE 100 down ahead of US interest rate decision

(Alliance News) - Stock prices in London closed mostly in the red on Wednesday, as investors eye the latest interest rate decision from the US Federal Reserve this evening.

Read more
1 May 2024 16:42

London close: Stocks fall ahead of US Fed decision

(Sharecast News) - London markets closed lower on Wednesday, as investors digested the latest UK manufacturing data and anticipated an impending policy announcement from the US Federal Reserve.

Read more
1 May 2024 11:55

LONDON MARKET MIDDAY: FTSE 100 treads water as Fed takes centre-stage

(Alliance News) - London's FTSE 100 traded off session highs heading into Wednesday afternoon, as some pre-Federal Reserve decision nerves kicked in.

Read more
1 May 2024 10:54

GSK raises profit outlook on strong vaccine, HIV drug sales

FY profit forecast raised to 8-10%

*

Read more
1 May 2024 08:57

LONDON MARKET OPEN: FTSE 100 shakes off New York slump before Fed

(Alliance News) - Stock prices in London opened mixed on Wednesday, with the FTSE 100 brushing off some pre-Federal Reserve decision trepidation to record an early rise, while the dollar climbed on the expectation that Jerome Powell will sound hawkish in his press conference later.

Read more
1 May 2024 08:50

TOP NEWS: GSK expects momentum to continue after strong first quarter

(Alliance News) - GSK PLC on Wednesday raised its annual earnings forecast, and said it expects sales growth at the top-end of guidance, after a "strong" start to the year.

Read more
1 May 2024 07:46

LONDON BRIEFING: GSK ups outlook; Next first-quarter beats forecast

(Alliance News) - Equities in London are called to open flat on Wednesday, ahead of the latest Federal Reserve interest rate decision, while a host of financial markets in mainland Europe and beyond are closed for public holidays.

Read more
1 May 2024 07:36

GSK lifts annual guidance on strong virus treatment sales

(Sharecast News) - UK pharmaceutical giant GSK lifted annual profits guidance on Wednesday, as it pinned its hopes on demand for its respiratory virus and shingles treatments.

Read more
30 Apr 2024 23:46

First trial over Zantac cancer claims set to begin in Chicago

April 30 (Reuters) - The first trial over claims that blockbuster heartburn drug Zantac, once sold by GSK and other companies, causes cancer is set to begin this week in Chicago.

Read more
30 Apr 2024 22:39

First trial over Zantac cancer claims set to begin in Chicago

April 30 (Reuters) - The first trial over claims that blockbuster heartburn drug Zantac, once sold by GSK and other companies, causes cancer is set to begin this week in Chicago.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.